We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Cardiac Marker POC Tests Now Widely Used in Hospitals

By LabMedica International staff writers
Posted on 04 Jan 2010
Cardiac marker point-of-care (POC) tests are now widely used in hospitals and have emerged as a successful model of the concept of point-of-care diagnostics, according to a new market report.

The 2008 world market for POC cardiac enzymes and tests is estimated at US$490 million, and growing at 12% a year for the past three years, according to healthcare market research publisher Kalorama Information (New York, NY, USA). More...
Cardiac markers are specific enzymes or proteins that tend to be concentrated when a cardiac event is likely to occur. Brain natriuretic peptide (BNP), CK-MB (creatine kinase, muscle and brain [subunits]), myoglobin, and troponin I/T are the most commonly tested markers. Testing for these markers can effectively indicate when intervention is or is not necessary. Lab-based tests can take up to 24 hours, which has driven demand for the point-of-care products that can deliver "stat” results.

"After many years of tests to prove effectiveness, there has been the stark realization that cardiac markers are useful to rule out or rule in the variety of cardiovascular conditions that are present in an ER [emergency room],” said Shara Rosen, the report's author.

The leaders in the cardiac enzyme POC market are Inverness's (Waltham, MA, USA) Triage, Siemens Healthcare's (Erlangen, Germany) Stratus, and Roche's (Nutley, NJ, USA) POC systems (Accutrend Plus, Roche Cardiac 200, Cobas h232). Of all POC testing that occurs in hospitals, cardiac marker tests are the fastest growing segment. Also at least another 20 companies market test strips for all or one of the marker panels. These companies' rapid tests help physicians triage cardiac patients more quickly.

Point-of-care or decentralized testing has long been the standard of care for glucose, but in other areas, results have been mixed. Products have been utilized, but never in the numbers that were predicted when the technologies were developed. The growth of cardiac markers is one part of a significant trend towards the use of POC tests, which now represent 15 percent of all tests conducted in hospitals.

POC testing has expanded because of studies that demonstrate the clinical effectiveness of these tests and technologic advancements that have increased their accuracy. Kalorama's research looked at the current state of glucose testing, as well as other emerging POC test categories, including the fast growing infectious disease and cholesterol test segments.

Kalorama Information supplies independent market research in the life sciences, as well as a full range of custom research services.

Related Links:

Kalorama Information




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
Immunofluorescence Analyzer
IFA System
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.